Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data

Many challenges arise when conducting a sequentially monitored medical product safety surveillance evaluation using observational electronic data captured during routine care. We review existing sequential approaches for potential use in this setting, including a continuous sequential testing method that has been utilized within the Vaccine Safety Datalink (VSD) and group sequential methods, which are used widely in randomized clinical trials.

[1]  H Merabet,et al.  The design and analysis of sequential clinical trials , 2013 .

[2]  Andrea J Cook,et al.  Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini‐Sentinel pilot , 2012, Pharmacoepidemiology and drug safety.

[3]  Malcolm Maclure,et al.  Design considerations in an active medical product safety monitoring system , 2012, Pharmacoepidemiology and drug safety.

[4]  D. Bernstein,et al.  Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus B conjugate (tetanus toxoid conjugate) vaccine pentacel , 2011 .

[5]  Ruihua Yin,et al.  H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. , 2011, American journal of preventive medicine.

[6]  W Katherine Yih,et al.  Near real‐time vaccine safety surveillance with partially accrued data , 2011, Pharmacoepidemiology and drug safety.

[7]  Steven J. Jacobsen,et al.  The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety , 2011, Pediatrics.

[8]  R. Platt,et al.  Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.

[9]  M. Kulldorff,et al.  A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance , 2011 .

[10]  W Katherine Yih,et al.  Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures , 2010, Pediatrics.

[11]  Ruihua Yin,et al.  Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. , 2010, American journal of epidemiology.

[12]  W Katherine Yih,et al.  Real-Time Surveillance to Assess Risk of Intussusception and Other Adverse Events After Pentavalent, Bovine-Derived Rotavirus Vaccine , 2010, The Pediatric infectious disease journal.

[13]  Lingling Li,et al.  A conditional sequential sampling procedure for drug safety surveillance , 2009, Statistics in medicine.

[14]  W Katherine Yih,et al.  An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. , 2009, Vaccine.

[15]  Richard Platt,et al.  Early adverse drug event signal detection within population‐based health networks using sequential methods: key methodologic considerations , 2009, Pharmacoepidemiology and drug safety.

[16]  M. Pichichero,et al.  Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial , 2009, Pediatrics.

[17]  Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. , 2008, MMWR. Morbidity and mortality weekly report.

[18]  Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. , 2008, MMWR. Morbidity and mortality weekly report.

[19]  D. Gillen,et al.  Frequentist evaluation of group sequential clinical trial designs , 2007, Statistics in medicine.

[20]  M. Kulldorff,et al.  Early detection of adverse drug events within population‐based health networks: application of sequential testing methods , 2007, Pharmacoepidemiology and drug safety.

[21]  Robert L Davis,et al.  Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events , 2007, Medical care.

[22]  Robert T. Chen,et al.  Active Surveillance of Vaccine Safety: A System to Detect Early Signs of Adverse Events , 2005, Epidemiology.

[23]  Scott S Emerson,et al.  Flexible implementations of group sequential stopping rules using constrained boundaries. , 2003, Biometrics.

[24]  KyungMann Kim.  Group Sequential Methods with Applications to Clinical Trials , 2001 .

[25]  R. Davis,et al.  The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. , 2000, Bulletin of the World Health Organization.

[26]  S. Emerson,et al.  A Unifying Family of Group Sequential Test Designs , 1999, Biometrics.

[27]  A. Tsiatis,et al.  Approximately optimal one-parameter boundaries for group sequential trials. , 1987, Biometrics.

[28]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[29]  J Whitehead,et al.  Group sequential clinical trials with triangular continuation regions. , 1983, Biometrics.

[30]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[31]  S. Pocock.  Group sequential methods in the design and analysis of clinical trials , 1977 .